gemfibrozil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1285	25812-30-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: gemfibrosil gemfibrozil decrelip lopizid	A lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol. Molecular weight: 250.34 Formula: C15H22O3 CLOGP: 3.94 LIPINSKI: 0 HAC: 3 HDO: 1 TPSA: 46.53 ALOGS: -3.95 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

gemfibrosil
gemfibrozil
decrelip
lopizid

A lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol.

Molecular weight: 250.34
Formula: C15H22O3
CLOGP: 3.94
LIPINSKI: 0
HAC: 3
HDO: 1
TPSA: 46.53
ALOGS: -3.95
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1.20	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.02 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	79.89 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	98 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Dec. 21, 1981	FDA	PFIZER PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Rhabdomyolysis	232.33	14.07	123	10422	43828	63434649
Drug hypersensitivity	70.95	14.07	158	10387	310529	63167948
Blood triglycerides increased	60.43	14.07	33	10512	12455	63466022
Coronary artery disease	58.19	14.07	46	10499	32331	63446146
Myocardial infarction	50.42	14.07	72	10473	99821	63378656
Blood creatine phosphokinase increased	49.94	14.07	41	10504	30389	63448088
Acute interstitial pneumonitis	43.70	14.07	12	10533	692	63477785
Cardiac failure congestive	40.00	14.07	62	10483	92371	63386106
Myalgia	37.32	14.07	78	10467	146451	63332026
Drug interaction	36.81	14.07	102	10443	229029	63249448
Cerebrovascular accident	35.43	14.07	64	10481	107960	63370517
Myopathy	34.24	14.07	22	10523	11169	63467308
Pancreatitis	33.45	14.07	41	10504	49014	63429463
Lip infection	33.33	14.07	7	10538	126	63478351
Off label use	31.08	14.07	40	10505	674422	62804055
Pancreatitis acute	29.50	14.07	29	10516	27137	63451340
Drug intolerance	26.69	14.07	9	10536	308652	63169825
Diabetes mellitus	24.92	14.07	38	10507	55772	63422705
Blood glucose increased	24.18	14.07	47	10498	83709	63394768
Drug ineffective	22.83	14.07	93	10452	1044672	62433805
Synovitis	21.07	14.07	3	10542	186915	63291562
Tendon rupture	19.93	14.07	14	10531	8225	63470252
Bronchitis viral	18.86	14.07	7	10538	1069	63477408
Arthropathy	18.37	14.07	8	10537	234784	63243693
Diabetes mellitus inadequate control	18.03	14.07	17	10528	15109	63463368
Infected bite	17.63	14.07	8	10537	2034	63476443
Chronic kidney disease	17.63	14.07	29	10516	45369	63433108
Microalbuminuria	16.60	14.07	5	10540	401	63478076
Joint swelling	16.57	14.07	18	10527	327648	63150829
Blood urea increased	16.31	14.07	21	10524	26358	63452119
Hyperlipidaemia	16.07	14.07	18	10527	19553	63458924
Hypertriglyceridaemia	15.99	14.07	11	10534	6248	63472229
Transient ischaemic attack	15.86	14.07	25	10520	37728	63440749
Wound	15.49	14.07	4	10541	163259	63315218
Infusion related reaction	15.41	14.07	11	10534	245510	63232967
Hypoglycaemia	15.30	14.07	32	10513	60033	63418444
Maternal exposure during pregnancy	14.97	14.07	9	10536	220053	63258424
Hypophagia	14.97	14.07	22	10523	31237	63447240
Renal failure	14.72	14.07	48	10497	117604	63360873
Granulocytopenia	14.57	14.07	10	10535	5662	63472815
Blood creatine phosphokinase MB increased	14.55	14.07	6	10539	1210	63477267
Myositis	14.19	14.07	12	10533	9254	63469223

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Rhabdomyolysis	550.36	12.74	350	14700	67813	34874068
Acute kidney injury	118.19	12.74	342	14708	304646	34637235
Blood creatine phosphokinase increased	113.40	12.74	117	14933	44740	34897141
Myalgia	99.83	12.74	150	14900	83960	34857921
Blood triglycerides increased	97.43	12.74	66	14984	14093	34927788
Coronary artery disease	76.47	12.74	99	14951	48206	34893675
Myocardial infarction	64.20	12.74	153	14897	120932	34820949
Drug hypersensitivity	56.58	12.74	114	14936	80415	34861466
Off label use	56.10	12.74	59	14991	419465	34522416
Polymyositis	53.43	12.74	21	15029	1432	34940449
Drug interaction	50.87	12.74	212	14838	225734	34716147
Cardiac failure congestive	50.49	12.74	111	14939	83159	34858722
Blood cholesterol increased	42.08	12.74	48	15002	20495	34921386
Pancreatitis	38.63	12.74	64	14986	38827	34903054
Drug level below therapeutic	33.52	12.74	24	15026	5591	34936290
Drug ineffective	32.15	12.74	96	14954	456655	34485226
International normalised ratio increased	32.02	12.74	66	14984	47261	34894620
Myopathy	30.72	12.74	31	15019	11523	34930358
Drug abuse	26.99	12.74	5	15045	99091	34842790
Hyperglycaemia	26.63	12.74	55	14995	39425	34902456
Haemodialysis	25.74	12.74	27	15023	10499	34931382
Chromaturia	24.91	12.74	31	15019	14489	34927392
Granulocytopenia	23.95	12.74	21	15029	6546	34935335
Chronic kidney disease	23.89	12.74	54	14996	41156	34900725
Blood glucose increased	22.95	12.74	72	14978	66646	34875235
Type 2 diabetes mellitus	22.49	12.74	31	15019	16001	34925880
General physical health deterioration	22.07	12.74	14	15036	128255	34813626
Thunderclap headache	21.46	12.74	6	15044	139	34941742
Asthenia	20.72	12.74	178	14872	245073	34696808
Angina unstable	20.18	12.74	25	15025	11628	34930253
Myositis	19.48	12.74	25	15025	12045	34929836
Iron deficiency anaemia	19.25	12.74	23	15027	10306	34931575
Blood glucose decreased	19.18	12.74	26	15024	13211	34928670
Angioedema	18.44	12.74	46	15004	37328	34904553
Hypertriglyceridaemia	17.74	12.74	20	15030	8428	34933453
Treatment noncompliance	17.61	12.74	38	15012	28062	34913819
Product use in unapproved indication	17.39	12.74	15	15035	117484	34824397
Arteriosclerosis coronary artery	17.30	12.74	24	15026	12461	34929420
Tricuspid valve incompetence	17	12.74	21	15029	9739	34932142
Lacrimation decreased	16.96	12.74	3	15047	6	34941875
Fanconi syndrome	16.77	12.74	10	15040	1710	34940171
Erosive duodenitis	16.75	12.74	10	15040	1714	34940167
Blood creatinine increased	16.71	12.74	83	14967	94893	34846988
Death	16.61	12.74	102	14948	397947	34543934
Intentional product use issue	16.32	12.74	3	15047	59813	34882068
Pyrexia	15.68	12.74	82	14968	332931	34608950
Muscular weakness	15.24	12.74	67	14983	72830	34869051
Chest pain	15.20	12.74	100	14950	126662	34815219
Otitis externa	15.14	12.74	8	15042	1085	34940796
Pneumonia haemophilus	14.88	12.74	6	15044	437	34941444
Supraventricular tachycardia	14.85	12.74	21	15029	11096	34930785
Breast neoplasm	14.72	12.74	3	15047	16	34941865
Reversible cerebral vasoconstriction syndrome	14.70	12.74	6	15044	451	34941430
Hyperlipidaemia	14.54	12.74	24	15026	14505	34927376
Renal tubular necrosis	14.49	12.74	25	15025	15655	34926226
Interstitial lung disease	14.49	12.74	5	15045	65277	34876604
C-reactive protein increased	14.16	12.74	3	15047	54095	34887786
Coronary artery stenosis	14.10	12.74	19	15031	9597	34932284
Metabolic acidosis	13.98	12.74	46	15004	43634	34898247
Hyperlactacidaemia	13.81	12.74	11	15039	3005	34938876
Paralysis	13.81	12.74	15	15035	6067	34935814
Renal failure	13.31	12.74	99	14951	130458	34811423
Intervertebral disc displacement	12.87	12.74	4	15046	135	34941746
Aortic valve sclerosis	12.86	12.74	7	15043	1007	34940874
High density lipoprotein decreased	12.77	12.74	11	15039	3349	34938532

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Rhabdomyolysis	734.11	12.66	411	20710	102720	79620547
Blood creatine phosphokinase increased	168.95	12.66	140	20981	65950	79657317
Blood triglycerides increased	163.34	12.66	89	21032	20951	79702316
Coronary artery disease	147.50	12.66	129	20992	65345	79657922
Acute kidney injury	142.00	12.66	377	20744	519027	79204240
Myocardial infarction	130.14	12.66	199	20922	183930	79539337
Myalgia	121.95	12.66	194	20927	185447	79537820
Cardiac failure congestive	88.25	12.66	145	20976	142257	79581010
Drug hypersensitivity	83.46	12.66	219	20902	298697	79424570
Off label use	82.19	12.66	72	21049	907143	78816124
Drug interaction	80.41	12.66	267	20854	414916	79308351
Pancreatitis	62.91	12.66	84	21037	68491	79654776
Myopathy	59.78	12.66	47	21074	20516	79702751
Drug ineffective	55.85	12.66	128	20993	1080785	78642482
Polymyositis	48.33	12.66	21	21100	3015	79720252
Granulocytopenia	44.16	12.66	31	21090	11400	79711867
Hyperlipidaemia	38.94	12.66	41	21080	26052	79697215
Hyperglycaemia	38.73	12.66	68	21053	70267	79653000
Myositis	37.67	12.66	35	21086	19133	79704134
Drug intolerance	36.88	12.66	12	21109	264107	79459160
International normalised ratio increased	36.80	12.66	74	21047	84647	79638620
Chromaturia	35.85	12.66	39	21082	25707	79697560
Blood glucose increased	33.81	12.66	86	21035	114889	79608378
Chronic kidney disease	32.66	12.66	61	21060	66093	79657174
Hypertriglyceridaemia	32.54	12.66	27	21094	12713	79710554
Acute interstitial pneumonitis	31.67	12.66	12	21109	1211	79722056
Blood creatinine increased	31.04	12.66	101	21020	154956	79568311
Renal failure	30.07	12.66	119	21002	200849	79522418
Treatment failure	29.19	12.66	5	21116	170481	79552786
Pancreatitis acute	28.67	12.66	49	21072	49555	79673712
Haemodialysis	27.92	12.66	29	21092	18139	79705128
Angioedema	27.90	12.66	62	21059	75973	79647294
Cerebrovascular accident	27.43	12.66	97	21024	155195	79568072
Drug abuse	27.36	12.66	5	21116	162686	79560581
Lip infection	27.21	12.66	7	21114	194	79723073
General physical health deterioration	27.10	12.66	20	21101	275218	79448049
Angina unstable	26.51	12.66	27	21094	16500	79706767
Joint swelling	25.89	12.66	23	21098	288623	79434644
Hypoglycaemia	25.82	12.66	72	21049	101522	79621745
Muscular weakness	25.53	12.66	97	21024	160632	79562635
Blood glucose decreased	25.38	12.66	33	21088	26201	79697066
Acute myocardial infarction	25.16	12.66	60	21061	76976	79646291
Pyrexia	24.99	12.66	94	21027	678615	79044652
Infusion related reaction	23.62	12.66	16	21105	230221	79493046
Arteriosclerosis coronary artery	23.10	12.66	26	21095	17790	79705477
Treatment noncompliance	21.91	12.66	45	21076	52223	79671044
Renal cyst	21.71	12.66	23	21098	14709	79708558
Lower respiratory tract infection	21.66	12.66	4	21117	129216	79594051
High density lipoprotein decreased	21.25	12.66	14	21107	4641	79718626
Coronary artery stenosis	21.14	12.66	21	21100	12463	79710804
Product use issue	20.97	12.66	15	21106	209807	79513460
Hyperkalaemia	20.66	12.66	72	21049	114326	79608941
Chest pain	20.22	12.66	136	20985	282168	79441099
Cardiac disorder	20.17	12.66	50	21071	65707	79657560
Acute coronary syndrome	19.54	12.66	26	21095	21107	79702160
Intentional product use issue	19.38	12.66	8	21113	152104	79571163
Erosive duodenitis	19.37	12.66	10	21111	2107	79721160
Blood urea increased	19.28	12.66	41	21080	48749	79674518
Condition aggravated	18.69	12.66	69	21052	501055	79222212
Thunderclap headache	18.25	12.66	6	21115	399	79722868
Rheumatoid arthritis	18.22	12.66	17	21104	208453	79514814
Blood cholesterol increased	18.08	12.66	56	21065	83664	79639603
Hypophagia	17.78	12.66	38	21083	45329	79677938
C-reactive protein increased	17.76	12.66	6	21115	129021	79594246
Intervertebral disc displacement	17.65	12.66	6	21115	443	79722824
Metabolic acidosis	17.64	12.66	55	21066	82474	79640793
Iron deficiency anaemia	17.04	12.66	27	21094	25645	79697622
Blood creatine phosphokinase MB increased	16.72	12.66	10	21111	2801	79720466
Wound	16.70	12.66	5	21116	116174	79607093
Fanconi syndrome	16.58	12.66	10	21111	2846	79720421
Tricuspid valve incompetence	16.33	12.66	23	21098	19689	79703578
Maternal exposure during pregnancy	16.11	12.66	8	21113	136530	79586737
Type 2 diabetes mellitus	16.03	12.66	42	21079	57080	79666187
Coronary artery occlusion	15.97	12.66	20	21101	15295	79707972
Liver function test abnormal	15.70	12.66	45	21076	64430	79658837
Myoglobinuria	15.55	12.66	7	21114	1093	79722174
Diabetes mellitus inadequate control	15.40	12.66	25	21096	24239	79699028
Carotid artery stenosis	15.32	12.66	15	21106	8743	79714524
Bronchitis viral	15.06	12.66	7	21114	1176	79722091
Ischaemic cardiomyopathy	15.02	12.66	14	21107	7681	79715586
Product complaint	14.84	12.66	18	21103	13331	79709936
Peripheral swelling	14.58	12.66	31	21090	269586	79453681
Tendon rupture	14.55	12.66	17	21104	12109	79711158
Infected bite	14.52	12.66	8	21113	1922	79721345
Hepatic steatosis	14.09	12.66	31	21090	37707	79685560
Aspartate aminotransferase increased	13.91	12.66	73	21048	138568	79584699
Alopecia	13.90	12.66	25	21096	231330	79491937
Diabetes mellitus	13.86	12.66	49	21072	78341	79644926
Mitral valve incompetence	13.67	12.66	26	21095	28539	79694728
COVID-19	13.61	12.66	13	21108	157661	79565606
Erectile dysfunction	13.49	12.66	18	21103	14646	79708621
Asthenia	13.46	12.66	200	20921	511489	79211778
Myocardial ischaemia	13.18	12.66	24	21097	25495	79697772
Otitis externa	12.93	12.66	8	21113	2382	79720885
Arthropathy	12.68	12.66	17	21104	177094	79546173

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C10AB04	CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, PLAIN Fibrates
FDA CS	M0199111	PPAR alpha
FDA MoA	N0000175375	Peroxisome Proliferator-activated Receptor alpha Agonists
CHEBI has role	CHEBI:35679	antilipemic drugs
FDA EPC	N0000175596	Peroxisome Proliferator Receptor alpha Agonist
MeSH PA	D000963	Antimetabolites
MeSH PA	D065687	Cytochrome P-450 CYP2C8 Inhibitors
MeSH PA	D065607	Cytochrome P-450 Enzyme Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D000960	Hypolipidemic Agents
MeSH PA	D057847	Lipid Regulating Agents
MeSH PA	D065606	Metabolic Side Effects of Drugs and Substances

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypertriglyceridemia	indication	302870006
Primary Prevention of Coronary Heart Disease	indication
Hypoalphalipoproteinemia	off-label use	190785000
Primary biliary cirrhosis	contraindication	31712002	DOID:12236
Disorder of gallbladder	contraindication	39621005	DOID:0060262
Acute nephropathy	contraindication	58574008
Leukopenia	contraindication	84828003	DOID:615
Impaired renal function disorder	contraindication	197663003
Disease of liver	contraindication	235856003	DOID:409
Calculus in biliary tract	contraindication	266474003
Anemia	contraindication	271737000	DOID:2355
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Breastfeeding (mother)	contraindication	413712001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	5.13	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Peroxisome proliferator-activated receptor alpha	Nuclear hormone receptor	Q07869	PPARA_HUMAN	AGONIST	EC50	4.23	IUPHAR	CHEMBL
Transthyretin	Secreted	P02766	TTHY_HUMAN		Kd	7	CHEMBL
Cytochrome P450 2C8	Enzyme	P10632	CP2C8_HUMAN		Ki	5.74	WOMBAT-PK
Cytochrome P450 2C9	Enzyme	P11712	CP2C9_HUMAN		Ki	4.52	WOMBAT-PK
Peroxisome proliferator-activated receptor gamma	Nuclear hormone receptor	P37231	PPARG_HUMAN		EC50	4.17	CHEMBL
Lipoprotein lipase	Enzyme	P06858	LIPL_HUMAN				WOMBAT-PK
CDGSH iron-sulfur domain-containing protein 1	Unclassified	Q9NZ45	CISD1_HUMAN		Ki	5.14	CHEMBL
Fatty acid-binding protein, liver	Unclassified		FABPL_RAT		Ki	5.73	CHEMBL

External reference:

ID	Source
4018639	VUID
N0000146952	NUI
D00334	KEGG_DRUG
4018639	VANDF
C0017245	UMLSCUI
CHEBI:5296	CHEBI
4TX	PDB_CHEM_ID
CHEMBL457	ChEMBL_ID
DB01241	DRUGBANK_ID
D015248	MESH_DESCRIPTOR_UI
3463	PUBCHEM_CID
3439	IUPHAR_LIGAND_ID
3899	INN_ID
Q8X02027X3	UNII
4719	RXNORM
4778	MMSL
523	MMSL
d00245	MMSL
002050	NDDF
35282000	SNOMEDCT_US
387189002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Lopid	HUMAN PRESCRIPTION DRUG LABEL	1	0071-0737	TABLET, FILM COATED	600 mg	ORAL	NDA	18 sections
Lopid	HUMAN PRESCRIPTION DRUG LABEL	1	0071-0737	TABLET, FILM COATED	600 mg	ORAL	NDA	18 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9130	TABLET, FILM COATED	600 mg	ORAL	ANDA	17 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9707	TABLET, FILM COATED	600 mg	ORAL	ANDA	18 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8354	TABLET, FILM COATED	600 mg	ORAL	ANDA	15 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8354	TABLET, FILM COATED	600 mg	ORAL	ANDA	15 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	10544-569	TABLET, FILM COATED	600 mg	ORAL	ANDA	18 sections
Gemfibrozil	Human Prescription Drug Label	1	16571-784	TABLET, FILM COATED	600 mg	ORAL	ANDA	15 sections
Gemfibrozil	Human Prescription Drug Label	1	16714-101	TABLET	600 mg	ORAL	ANDA	18 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	21695-732	TABLET, FILM COATED	600 mg	ORAL	ANDA	17 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	24658-260	TABLET, FILM COATED	600 mg	ORAL	ANDA	17 sections
GEMFIBROZIL	HUMAN PRESCRIPTION DRUG LABEL	1	31722-128	TABLET	600 mg	ORAL	ANDA	11 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	31722-225	TABLET	600 mg	ORAL	ANDA	11 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	33261-146	TABLET, FILM COATED	600 mg	ORAL	ANDA	17 sections
GEMFIBROZIL	HUMAN PRESCRIPTION DRUG LABEL	1	42806-260	TABLET	600 mg	ORAL	ANDA	11 sections
GEMFIBROZIL	HUMAN PRESCRIPTION DRUG LABEL	1	42806-260	TABLET	600 mg	ORAL	ANDA	11 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	43063-745	TABLET	600 mg	ORAL	ANDA	11 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	43063-745	TABLET	600 mg	ORAL	ANDA	11 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	43063-745	TABLET	600 mg	ORAL	ANDA	11 sections
GEMFIBROZIL	HUMAN PRESCRIPTION DRUG LABEL	1	43063-921	TABLET	600 mg	ORAL	ANDA	11 sections
GEMFIBROZIL	HUMAN PRESCRIPTION DRUG LABEL	1	43063-921	TABLET	600 mg	ORAL	ANDA	11 sections
GEMFIBROZIL	HUMAN PRESCRIPTION DRUG LABEL	1	43063-921	TABLET	600 mg	ORAL	ANDA	11 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	43353-090	TABLET, FILM COATED	600 mg	ORAL	ANDA	18 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	43353-772	TABLET, FILM COATED	600 mg	ORAL	ANDA	21 sections
GEMFIBROZIL	HUMAN PRESCRIPTION DRUG LABEL	1	43602-452	TABLET	600 mg	ORAL	ANDA	10 sections
Gemfibrozil	Human Prescription Drug Label	1	50090-2450	TABLET, FILM COATED	600 mg	ORAL	ANDA	15 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	50090-2902	TABLET	600 mg	ORAL	ANDA	11 sections
GEMFIBROZIL	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5808	TABLET	600 mg	ORAL	ANDA	11 sections
GEMFIBROZIL	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5808	TABLET	600 mg	ORAL	ANDA	11 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	50268-350	TABLET	600 mg	ORAL	ANDA	11 sections